Opinion/decision on a Paediatric investigation plan (PIP): lasmiditan, decision type: , therapeutic area: , PIP number: P/0056/2021
Opinion/decision on a Paediatric investigation plan (PIP): bimekizumab, decision type: , therapeutic area: , PIP number: P/0339/2022
Opinion/decision on a Paediatric investigation plan (PIP): Dovprela (previously Pretomanid FGK),Pretomanid, decision type: , therapeutic area: , PIP number: P/0292/2022
Opinion/decision on a Paediatric investigation plan (PIP): Bempedoic acid (ETC-1002), decision type: , therapeutic area: , PIP number: P/0351/2022
Opinion/decision on a Paediatric investigation plan (PIP): Avacopan, decision type: , therapeutic area: , PIP number: P/0266/2022
Withdrawn application: Zefylti, filgrastim, Date of withdrawal: 08/06/2023, Initial authorisation
Human medicines European public assessment report (EPAR): Eurartesim, piperaquine tetraphosphate,artenimol, Malaria, Date of authorisation: 27/10/2011, Revision: 13, Status: Authorised
COVID-19 public health emergency of international concern (2020-23)
Opinion/decision on a Paediatric investigation plan (PIP): Vitrakvi,Larotrectinib, decision type: , therapeutic area: , PIP number: P/0289/2022
Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, HIV Infections, Date of authorisation: 01/03/2004, Revision: 54, Status: Authorised